Lenacapavir, a new twice-yearly injectable HIV prevention drug, promises a major shift in the global fight against HIV.
With a dramatically reduced price of $40 per year, access will expand significantly to 120 low- and middle-income countries by 2027.
This breakthrough, proven highly effective in clinical trials, could substantially decrease new HIV infections worldwide.
However, challenges remain; ensuring equitable distribution and continued funding are crucial to fully realize lenacapavir's potential impact.
